You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK)股價曾瀉逾八成 產品治療新冠非住院患者試驗未達統計學顯着性
阿思達克 12-28 09:51
開拓藥業-B(09939.HK)普克魯胺治療新冠非住院患者試驗未達統計學顯着性,今早股價急瀉,最低暫見6.91元,瀉84.7%,現報11.92元,瀉73.6%,成交大增至2.7億元。 開拓藥業指,公司於昨日(27日)提供普克魯胺治療新冠非住院患者全球多中心臨牀試驗的進展報告,該項III期臨牀試驗的中期分析未達到統計學顯着性,試驗目的是評估普克魯胺治療非住院新冠患者的有效性和安全性。公司將向各監管機構,包括美國食品藥品監督管理局(FDA)尋求同意以修改臨牀試驗方案,計劃繼續招募只有基礎性疾病和/或無新冠疫苗接種史的高風險新冠患者。根據中期分析,公司未發現普克魯胺的安全性問題,亦未有藥物相關的嚴重不良事件報告。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account